Towa Pharmaceutical Co., Ltd.
【Towa Pharmaceutical】Announcement of Executive Changes | June 24, 2026
Towa Pharmaceutical announced the personnel changes at the General Meeting of Shareholders and Board of Directors held on June 24, 2026, revealing new and reappointed directors. President and CEO Ichiro Yoshida will continue in his role, while Koji Nakamura was newly appointed as a director.
Key Figures
- Management structure: President and CEO Ichiro Yoshida, reappointment and new appointment of other executives
- Newly appointed director: Koji Nakamura (Director, Head of the President’s Office and in charge of the Management Strategy Division)
- Date of executive decision: June 24, 2026
AI要約
Overview of Executive Changes
Towa Pharmaceutical resolved upon its executive personnel changes at the Shareholders’ Meeting and Board of Directors held on June 24, 2026. President and CEO Ichiro Yoshida will continue serving, and Koji Nakamura, who is also the Head of the President’s Office and in charge of the Management Strategy Division, was newly appointed as a director. Other executives were also reappointed, resulting in a stable leadership structure.
Impact of the Executive Changes and Future Outlook
The recent executive personnel changes aim to maintain and stabilize the company's management structure, which is expected to play an important role in advancing future business strategies. In particular, the appointment of Koji Nakamura as the person responsible for management strategy is anticipated to contribute to future business development and the promotion of new businesses. The appointment also includes responsible executives, strengthening the accountability system in accordance with the Pharmaceuticals and Medical Devices Act.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
